Novo nordisk to acquire cardior pharmaceuticals and strengthen pipeline in cardiovascular disease

BagsvÆrd, denmark, and han n over, germany, 25 march, 2024 – novo nordisk and cardior pharmaceuticals today announced that novo nordisk has agreed to acquire cardior for up to 1.025 billion euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
NVO Ratings Summary
NVO Quant Ranking